Q1-FY26 · Abhay Soi
Eida margin is an incorrect sort of thing... What we have to see is do we have superior return on capital profile over there or not? Your EBITDA per bed will increase and your ROC will increase.
MAXHEALTH / language trends
Read confidence between the lines.
Max Healthcare Institute · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q1-FY26 · Abhay Soi
Because the higher payer mix your EBITDA margin... international business is going by 32%. Supposedly it's higher margin business in value term. But in percentage terms, it's a lower margin business. When you do robotics or you do transplants or you do any of the high-end business, surgical business, it gives you less margins in percentage term, but it gives you more in value terms.
Q1-FY26 · Abhay Soi
The first couple of quarters always the weakest because you're kind of integrating IT systems, we changed the name, all the licenses including transplant licenses, blood bank licenses, we had to reapply for each one of these. So those have been coming through. And also equipment is out of life. We've ordered all the equipment they've been coming in phases. All the building blocks have been put in this particular listing.
Q2-FY26 · Abhay Havaldar
We are pleased to report that the network has maintained its strong growth momentum through the first half of FY26. For the second quarter, revenue grew by 21% year-on-year while operating EBITDA increased by 23%, thereby extending our track record to 20 consecutive quarters of consistent growth.
Q2-FY26 · Yogesh S. R. Bhatt
The insurance may growth may have come down, but your cash growth may if you're not doing cashless, what happens? It's not necessary that you lose the patient, the patient also gets converted to cash paying. Because he goes later doesn't necessarily change the hospital because of which I think what you need to look at is the overall occupancy between cash and insurance and that's fungible.
Q2-FY26 · Yogesh S. R. Bhatt
Oncology bunker is not operational over there right now. The idea was for us to fill up the hospital and then start to distill the pyramids. So I think we are at a stage where we have to start doing that now. You're going to see higher ARPOBs, you're going to see improvement expansion of margins through both patient mix, clinical mix including higher amount of share of oncology once the radiation starts over there.
Q3-FY26 · Abhai
We are pleased to share that the network delivered its 21st consecutive quarter of year-on-year growth in quarter 3 despite excessive unanticipated seasonal softness due to lack of vector-borne diseases and transitionary external factors.
Q3-FY26 · Abhai
I think the big deterrent on our growth has been capacity. Essentially if I go beyond the seasonality of it and whatever one-time disruptions which are back to normal, everything that we've acquired or the new capacity that we set up have been ramping up very well.
Q3-FY26 · Management
Annualized EBITDA per bed for the network stood at ₹71 lakhs versus ₹73 lakhs in both Q3 FY25 and the previous quarter. The two big factors affecting profitability were seasonality and the insurance disruption where we replaced all of that with institutional business, so occupancy didn't get impacted but quality of revenues got impacted.